Skip to main content

Advertisement

Table 1 Demographic and disease characteristics at baseline

From: Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study

Parameters CHB group (n = 32) Non-CHB group (n = 128) p valuea
Matched parameters
 Female, n (%) 27 (84) 108 (84) 1.000
 Age (years) 49 (38–56) 49 (38–57) 0.964
 DAS28-CRP 4.6 (3.5–5.0) 4.6 (3.8–5.3) 0.791
Demographic characteristics
 Age of onset (years) 44 (31–52) 45 (33–53) 0.948
 Disease duration (months) 36 (9–113) 36 (12–84) 0.805
  Short duration (<6 months) 3 (9) 19 (15) 0.476
  Intermediate duration (6–24 months) 12 (38) 39 (30) 0.501
  Long duration (>24 months) 17 (53) 70 (55) 0.887
Disease characteristics
 TJC28 6 (2–10) 6 (3–10) 0.914
 SJC28 4 (1–8) 4 (2–6) 0.523
 PainVAS 4 (2–5) 4 (3–6) 0.131
 PtGA 5 (3–6) 5 (3–6) 0.355
 PrGA 5 (3–5) 5 (3–6) 0.276
 HAQ 0.6 (0–1.3) 0.6(0.1–1.2) 0.888
 CRP (mg/L) 12.1 (3.8–44.2) 12.1 (4.8–32.0) 0.543
 ESR (mm/h) 36 (20–62) 50 (24–75) 0.162
 RF positivity, n (%) 23 (72) 96 (75) 0.746
 ACPA positivity, n (%) 23 (72) 101 (79) 0.448
 SDAI 22.1 (13.6–31.3) 21.2 (14.6–29.3) 0.320
 CDAI 19 (12–28) 20 (13–26) 0.332
 RAPID3 3.3 (2.1–4.6) 3.6 (2.7–5.2) 0.128
 MMP-3 (ng/mL) 184 (86–453) 155 (86–358) 0.440
Liver function
 AST (U/L) 18 (14–25) 16 (14–21) 0.630
 ALT (U/L) 18 (12–29) 15 (10–21) 0.769
Radiographic status
 Bony erosions, n (%) 25 (78) 96 (75) 0.742
 JSN subscore 5.5 (0–18.8) 3.0 (1.0–9.8) 0.078
 JE subscore 6.0 (1.0–22.0) 4.0 (0.3–10.0) 0.009
 mTSS 11.0 (1.3–36.3) 8.0 (2.0–20.8) 0.021
Previous medications, n (%)
 Treatment-naïveb 11 (34) 55 (43) 0.431
 GCs 14 (44) 48 (38) 0.562
 MTX 16 (50) 49 (38) 0.283
 LEF 6 (19) 34 (27) 0.417
 SSZ 4 (13) 1 (1) 0.005
 HCQ 10 (31) 12 (9) 0.006
 CysA 1 (3) 5 (4) 0.853
 Biologic agents 1 (3) 3 (2) 0.821
  1. Data are presented as median (interquartile range (IQR)) or number (percentage (%))
  2. ACPA anti-cyclic citrullinated peptide antibody, ALT alanine aminotransferase, AST aspartate transaminase, CDAI Clinical Disease Activity Index, CHB chronic hepatitis B virus infection, CRP C-reactive protein, CysA cyclosporin A, DAS28 Disease Activity Score 28-joint assessment, DMARD disease-modifying anti-rheumatic drug, ESR erythrocyte sedimentation rate, GC glucocorticosteroid, HAQ Stanford Health Assessment Questionnaire, HCQ hydroxychloroquine, JE joint erosion, JSN joint space narrowing, LEF leflunomide, mTSS modified total Sharp score, MMP-3 matrix metalloproteinase-3, MTX methotrexate, NA not applicable, Pain VAS pain visual analog scale, PrGA provider global assessment of disease activity, PtGA patient global assessment of disease activity, RA rheumatoid arthritis, RAPID3 Routine Assessment of Patient Index Data 3, RF rheumatoid factor, SDAI Simplified Disease Activity Index, SJC28 28-joint swollen joint counts, SSZ sulfasalazine, TJC28 28-joint tender joint count
  3. aCompared between the CHB group and the non-CHB group using conditional logistic regression analysis: bold p values are significant
  4. bWithout glucocorticosteroid or DMARD therapy for 6 months before enrollment